Pharmacologic targeting of midasin (MDN1) reveals a potential therapeutic vulnerability in ESR1-mutant breast cancer

IntroductionAlthough most cases of estrogen receptor-positive (ER+) breast cancer initially respond to endocrine therapy, many patients ultimately develop resistance. A major contributor to endocrine resistance in metastatic disease is the acquisition of constitutively active somatic mutations in th...

Descripció completa

Dades bibliogràfiques

Autors principals:	Mounika Pamukuntla, Afia Ohemeng, Bipika Banjara, Manasa Kotina, Jillian L. Pope, Simak Ali, Selina Darling-Reed, Matthew E. Burow, Madhavi Gangapuram, Suresh Eyunni, Jaylen Thomas, Aaron Hilliard, A. Michael Davidson, Elizabeth Henderson, Syreeta L. Tilghman
Format:	Artigo
Idioma:	Inglês
Publicat:	Frontiers Media S.A. 2026-07-01
Col·lecció:	Frontiers in Pharmacology
Matèries:	breast cancer endocrine resistance estrogen receptor estrogen receptor mutations midasin ribozinoindoles
Accés en línia:	https://www.frontiersin.org/articles/10.3389/fphar.2026.1852788/full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!